(Fighting New Coronary Pneumonia) US FDA Approves Emergency Use Authorization for "Antibody Cocktail" Therapy

  China News Service, Houston, November 21. The U.S. Food and Drug Administration (FDA) approved the emergency drug use authorization for the "antibody cocktail" therapy on the 21st local time. This new crown single-dose antibody mixture was approved for the treatment of new crown disease. , Moderately infected persons.

US President Trump took the experimental drug when he contracted the new crown virus in October.

  According to the FDA's official website, the therapy is suitable for patients with new crowns of at least 40 kg who are 12 years old and older.

This therapy is not suitable for hospitalized patients with new coronary pneumonia and patients who need oxygen therapy.

The FDA said that early studies have shown that this therapy reduces the viral load and shortens the time it takes for out-of-hospital COVID-19 patients to relieve their symptoms.

The FDA is still evaluating the safety and effectiveness of this therapy.

  The "antibody cocktail" therapy was developed by Regeneron Pharmaceuticals.

It is a combination of two monoclonal antibody drugs casirivimab and imdevimab.

They are antibodies that specifically target the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), designed to prevent the virus from attaching to and entering human cells.

According to the FDA, the "antibody cocktail" therapy requires intravenous injection of both drugs.

  White House doctor Sean Conley said earlier that Trump had received "antibody cocktail" therapy with a single dose of 8 grams.

  According to CNN, this is the second antibody drug approved by the FDA for the treatment of new coronary pneumonia.

In early November, the FDA urgently approved bamlanivimab, a single antibody drug from Eli Lilly and Company, for the treatment of patients with mild to moderate COVID-19 infection.

  It is worth noting that according to the US news website "Politics", one of the main disadvantages of antibody therapies is that they are difficult to produce quickly and on a large scale.

  According to the Associated Press, the Trump administration has signed hundreds of millions of dollars in agreements with Regeneron Pharmaceuticals and Eli Lilly to purchase 300,000 doses of drugs from them.

The government stated that these drugs will be provided to patients free of charge.

Patients may need to pay part of the cost of intravenous injections.

  Regeneron Pharmaceuticals said that by the end of November this year, the amount of "antibody cocktail" therapy can be used to treat 80,000 patients, and by the end of January 2021, it will be able to provide drugs to 300,000 patients.

  According to statistics from Johns Hopkins University, as of 11 p.m. Eastern Time on November 21, the cumulative number of confirmed cases of new coronary pneumonia in the United States exceeded 12.08 million, and the cumulative death toll exceeded 255,000.

(Finish)